Monitoring Response to Targeted Therapy in Non-Small Cell Lung Cancer Using 18F..

[18]氟-2-脱氧葡萄糖([18]F-FDG)正电子发射断层扫描和计算机断层扫描(PET/CT)是一种强大的肿瘤检测和监测各种恶性肿瘤治疗反应的成像工具。然而，对治疗反应的评估可能会受到其非特异性(炎症/反应细胞摄取)的负面影响。[18]F标记的二聚体RGD多肽[F]FPA-PEG3-E[c(RGDyK)]2([18]F]FPPRGD2是斯坦福大学最近开发的一种用于肿瘤整合素表达成像的新型放射性药物，它可以更准确地评估肺癌患者对抗血管生成治疗的反应。我们已经成功地进行了小动物成像研究，证明了 [18][18]FPPRGD2 PET成像和监测抗血管生成治疗反应的可能性。人类(健康志愿者)的第一次注射[[18]F]FPPRGD2，然后是PET/CT，已经在2009年6月22日完成。磁性纳米蛋白质芯片能够以高通量和多路复用的形式对小鼠或人类血清样本进行蛋白质谱分析，是探索癌症信号通路网络的许多方面的一种令人兴奋的强大工具。血管内皮生长因子(VEGF)和人表皮生长因子受体(HER-1/EGFR)已被确定为治疗非小细胞肺癌(NSCLC)的关键分子靶点。常规的肿瘤增强CT成像依赖于肿瘤大小的变化来评估治疗反应。然而，靶向治疗可能不会导致病变大小的显著变化。因此，功能分子成像可能提供更早和更准确的手段来评估这些新药的疗效。 基于有希望的初步临床前结果，我们将尝试招募50名NSCLC患者来研究[[18]F]FPPRGD2 PET/CT是可行的假设，并结合Magonano传感器测量EGFR通路可以评估和预测NSCLC对靶向Tarceva/Aventtin或Vandetanib治疗的反应。目的1：评价f[18]F]FPPRGD2 PET/CT扫描在非小细胞肺癌诊断中的有效性和可行性。目的：评价[[18]F]FPPRGD2 PET/CT和磁性纳米传感器联合应用对非小细胞肺癌患者Tarceva/Avestin或Vandetanib治疗的早期评估和预测疗效。

Fluorine-18 2-Fluoro 2-deoxyglucose ( [18] F FDG) positron emission tomography and computed tomography (PET/CT) is a powerful imaging tool for cancer detection and monitoring response to therapy in various malignancies. However, evaluation of response to therapy may be negatively influenced by its non-specificity (uptake in inflammatory/reactive cells). [18] F-labeled dimeric RGD peptide [^¿F] FPA-PEG3-E[c(RGDyK)]2 ( [18] F] FPPRGD2), a novel radiopharmaceutical recently developed at Stanford for imaging of tumor integrin expression, may provide more accurate evaluation of response to anti-angiogenesis therapy in subjects with lung cancer. We already successfully performed small animal imaging studies demonstrating the feasibility of [ [18] F] FPPRGD2 PET imaging and the possibility to monitor response to anti-angiogenesis therapy. The first in human (healthy volunteer) administration of [ [18] F] FPPRGD2 followed by PET/CT was already done on June 22, 2009. Magneto-nano protein chips (magnetic chips) enable protein profiling of mouse or human serum samples in a high throughput and multiplexed format, and represent an exciting, powerful tool for exploring many facets of the signaling pathway network in cancer. The vascular endothelial growth factor (VEGF) and human epidermal growth factor receptor (HER-1/EGFR) have been identified as key molecular targets for therapy in non-small-cell lung cancer (NSCLC). Conventional tumor imaging with contrast enhanced CT relies on changes in size to evaluate response to therapy. However, targeted therapies may not cause a significant change in the size of the lesions. Therefore, functional molecular imaging may provide earlier and more accurate means of assessing response to these new drugs. Based on the promising preliminary preclinical results we will attempt to recruit 50 subjects with NSCLC to investigate the hypotheses that [[18] F] FPPRGD2 PET/CT is feasible and that in combination with magnetonano sensors measurements of EGFR pathways can assess and predict the response to targeted Tarceva/Avastin or Vandetanib therapy in NSCLC. Aim 1: Evaluate the efficacy and feasibility of f [18] F] FPPRGD2 PET/CT scanning in patients with NSCLC. Aim 2: Evaluate the combination of [ [18] F] FPPRGD2 PET/CT and magneto-nano sensors for early assessment and prediction of response to Tarceva/Avastin or Vandetanib therapy in patients with NSCLC.